Global Anaphylaxis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 220 pages | ID: G146BE1841EEN
Precision Business Insights (PBI)

Abstracts

Global Anaphylaxis Treatment Market

Anaphylaxis is a serious, allergic reaction that is to be treated immediately. Anaphylaxis is a life-threatening reaction with cardiovascular, respiratory, gastrointestinal, or cutaneous manifestations resulting from exposure to an offending agent, usually insect sting, food, physical factor, or medication. It is typical causes more than one of the symptoms such as throat or tongue swelling, itchy rash, vomiting, shortness of breath, light-headedness, and low blood pressure. Anaphylaxis occurs due to the release of mediators from white blood cells that initiate immunological or nonimmunologic mechanisms. Anaphylaxis is primarily treated by epinephrine through IV route or intra-muscular route. Addition to epinephrine antihistamines, H2 blockers, vasodilators, and steroids are used to relieve the symptoms.

Global Anaphylaxis Treatment Market is driven by the increase in the incidence of anaphylaxis around the world. In addition, promising product launches by the major companies such as Teva Pharmaceuticals, Inc. and others, an increase in awareness regarding available treatment options for anaphylaxis among healthcare professionals and patients are boosting the market revenue growth of anaphylaxis treatment market. However, the cost of the treatment, lack of awareness in underdeveloped regions regarding the allergic reaction treatment, and side effects of the drugs used for treatment are hindering the growth of anaphylaxis treatment market.

Global Anaphylaxis treatment market has been segmented based on drug class, route of administration and distribution channel

Based on drug class, Anaphylaxis Treatment Market is segmented into

• Adrenergic Agents (Epinephrine)
• Anti-Histamines
• Others

Based on route of administration, Anaphylaxis treatment market is segmented into

• Parenteral
• Oral
• Others

Based on distribution channel, Anaphylaxis treatment market is segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Anaphylaxis treatment market is much consolidated in nature due to the presence of very few players in the market. The introduction of the auto-injectors to treat the anaphylaxis revolutionised the anaphylaxis treatment market. Market players are increasing their market presence by collaborations and partnerships. In addition, marketers focusing on the product launches and expanding into other regions for better revenue realization. For instance, in 2015, ALK-Abelló and bioCSL (CSL Limited) entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as GRAZAX in Europe and GRASTEK in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bio CLS will undertake registration and commercialisation of the products. Companies reducing the costs by introducing the generic, cheaper versions of the epinephrine auto-injectors to penetrate into the market. For instance, Mylan N.V. has introduced the generic version of EpiPen at half the price. The initial pack of two was sold at US$600 until December 2016 which will be sold at US$ 300 from January 2017.

Geographically Anaphylaxis treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to lead the anaphylaxis treatment market due to increase in the incidence of anaphylaxis, lifestyle changes and raising awareness about available treatment for anaphylaxis among healthcare professionals. Europe anaphylaxis treatment market expected to grow at healthier rate due to increased adoption of the new technologies in the treatment of anaphylaxis. Asia Pacific anaphylaxis treatment market expected to grow at faster rates owing to larger pool patients coupled with high medical unmet need in the region.

Some of the market players in Anaphylaxis treatment market are ALK-Abelló (Denmark), Impax Laboratories Inc. (U.S.), Lincoln Medical Ltd. (New Zealand), Mylan NV ( U.S.), Adamis Pharmaceutical Corporation (U.S.), MannKind Corporation (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.K), Merck & Co., Inc. (U.S.) to name a few.

In June 2017, The U.S. Food and Drug Administration (FDA) approved Adamis Pharmaceutical’s epinephrine injection, “symjepi” (0.3mg/ml) for the emergency treatment of allergic reactions, including anaphylaxis.

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ANAPHYLAXIS TREATMENT MARKET INTRODUCTION

2.1. Global Anaphylaxis Treatment Market – Taxonomy
2.2. Global Anaphylaxis Treatment Market –Definitions
  2.2.1. Drug Class
  2.2.2. Route of Administration
  2.2.3. Distribution Channel

3. GLOBAL ANAPHYLAXIS TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anaphylaxis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Anaphylaxis Treatment Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Anaphylaxis Treatment Market – Product Innovations

4. GLOBAL ANAPHYLAXIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ANAPHYLAXIS TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Adrenergic Agents (Epinephrine)
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Anti-Histamines
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Others
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis

6. GLOBAL ANAPHYLAXIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Parenteral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Oral
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Others
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis

7. GLOBAL ANAPHYLAXIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Retail Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis

8. GLOBAL ANAPHYLAXIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.5.3. Market Opportunity Analysis
8.6. Global Anaphylaxis Treatment Market - Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2017 – 2023

9. NORTH AMERICA ANAPHYLAXIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Adrenergic Agents (Epinephrine)
  9.1.2. Anti-Histamines
  9.1.3. Others
9.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Parenteral
  9.2.2. Oral
  9.2.3. Others
9.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Retail Pharmacies
  9.3.2. Hospital Pharmacies
  9.3.3. Online Pharmacies
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Anaphylaxis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
9.6. North America Anaphylaxis Treatment Market Dynamics – Trends

10. EUROPE ANAPHYLAXIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Adrenergic Agents (Epinephrine)
  10.1.2. Anti-Histamines
  10.1.3. Others
10.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Parenteral
  10.2.2. Oral
  10.2.3. Others
10.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Retail Pharmacies
  10.3.2. Hospital Pharmacies
  10.3.3. Online Pharmacies
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Anaphylaxis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
10.6. Europe Anaphylaxis Treatment Market Dynamics – Trends

11. ASIA-PACIFIC ANAPHYLAXIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Adrenergic Agents (Epinephrine)
  11.1.2. Anti-Histamines
  11.1.3. Others
11.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Parenteral
  11.2.2. Oral
  11.2.3. Others
11.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Retail Pharmacies
  11.3.2. Hospital Pharmacies
  11.3.3. Online Pharmacies
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Anaphylaxis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
11.6. Europe Anaphylaxis Treatment Market Dynamics – Trends

12. LATIN AMERICA ANAPHYLAXIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Adrenergic Agents (Epinephrine)
  12.1.2. Anti-Histamines
  12.1.3. Others
12.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Parenteral
  12.2.2. Oral
  12.2.3. Others
12.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Retail Pharmacies
  12.3.2. Hospital Pharmacies
  12.3.3. Online Pharmacies
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Anaphylaxis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Anaphylaxis Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA ANAPHYLAXIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Adrenergic Agents (Epinephrine)
  13.1.2. Anti-Histamines
  13.1.3. Others
13.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Parenteral
  13.2.2. Oral
  13.2.3. Others
13.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Retail Pharmacies
  13.3.2. Hospital Pharmacies
  13.3.3. Online Pharmacies
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Anaphylaxis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
13.6. MEA Anaphylaxis Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Vins Bioproducts Limited (India)
  14.2.2. Bharat Serum and Vaccines Limited (India)
  14.2.3. CSL Limited (Victoria), Rare Disease Therapeutics, Inc. (U.S.)
  14.2.4. F. Hoffmann-La Roche AG (Switzerland)
  14.2.5. Instituto Bioclon, S.A. de C.V.(Mexico)
  14.2.6. Incepta Vaccine Ltd. (Bangladesh)
  14.2.7. BTG Plc (U.K)
  14.2.8. Merck & Co., Inc. (U.S)
  14.2.9. Pfizer Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS